Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

S-P files NDA for OTC Zegerid

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough has filed an Rx-to-OTC switch application with FDA for its proton-pump inhibitor/antacid combination Zegerid (20 mg omeprazole/1100 mg sodium bicarbonate) to treat frequent heartburn, according to a March 11 release. The new drug application was filed under the terms of an October 2006 licensing agreement with San Diego-based Santarus, which discussed the product during a March 3 earnings call (1"The Tan Sheet" March 10, 2008, p. 4). Under standard FDA review, the product could be approved and on the market in early 2009. The immediate-release formula could provide an advantage in the market against Procter & Gamble's OTC PPI Prilosec OTC and private label equivalents...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel